Fluorine-18-α-Methyltyrosine Positron Emission Tomography (18F-FMT PET) for Therapy Response in Lung Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00826033
Recruitment Status : Completed
First Posted : January 21, 2009
Last Update Posted : January 21, 2009
Information provided by:
Gunma University

Brief Summary:

L-[3-18F]-α-methyltyrosine (18F-FMT) is an amino-acid tracer for positron emission tomography (PET). The investigators evaluated the value of 18F-FMT PET for the assessment of therapy response in patients with lung cancer as compared with that of 2-[18F]-fluoro-2-deoxy-D-glucose (18F-FDG) PET.

The patients with lung cancer underwent PET studies with 18F-FDG and 18F-FMT before and after radio-/chemotherapy. The investigators used the ratio of the SUVmax of the mediastinal (N2) lymph node to the SUVmax of the primary tumor (N/P ratio ). All patients were divided into two groups of N/P ratio<1 and N/P ratio≥1, and the survival time was estimated by Kaplan-Meier method.

Condition or disease
Non-Small Cell Lung Cancer

Study Type : Observational
Time Perspective: Prospective
Official Title: Fluorine-18-α-Methyltyrosine Positron Emission Tomography to Measure Therapy

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Lung Cancer
U.S. FDA Resources

Therapy monitoring

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   20 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
This study was conducted at the Gunma University Hospital.

Inclusion Criteria:

  • primary lung cancer All patients received first-line chemotherapy

Exclusion Criteria:

  • Patients with diabetus mellitus

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00826033

Gunma University Graduate School of Medicine
Gunma, Japan, 371-8511
Sponsors and Collaborators
Gunma University
J~pharma Identifier: NCT00826033     History of Changes
Other Study ID Numbers: Mol Imaing 1
First Posted: January 21, 2009    Key Record Dates
Last Update Posted: January 21, 2009
Last Verified: January 2009

Keywords provided by Gunma University:
Positron emission tomography
Lung cancer

Additional relevant MeSH terms:
Lung Neoplasms
Carcinoma, Non-Small-Cell Lung
Respiratory Tract Neoplasms
Thoracic Neoplasms
Neoplasms by Site
Lung Diseases
Respiratory Tract Diseases
Carcinoma, Bronchogenic
Bronchial Neoplasms
Cariostatic Agents
Protective Agents
Physiological Effects of Drugs
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action